NCT00616161View on ClinicalTrials.gov

A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

August 31, 2007

Conditions
Heart Failure
Interventions
DRUG

Istaroxime

0.5 microgram/kg/min IV for 6 hours

DRUG

Istaroxime

1.0 microgram/kg/min IV for 6 hours

DRUG

Istaroxime

1.5 microgram/kg/min IV for 6 hours

DRUG

Placebo

Placebo

Sponsors

Collaborators (1)

MDS Pharma Services
All Listed Sponsors
collaborator

MDS Pharma Services

INDUSTRY

lead

sigma-tau i.f.r. S.p.A.

INDUSTRY

NCT00616161 - A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function | Biotech Hunter | Biotech Hunter